MRGPRX2 fails key CSU test as Evommune drops urticaria program

Evommune’s Phase IIb miss in chronic spontaneous urticaria removes one of the most advanced tests of MRGPRX2 in the indication, raising questions about whether blocking a single mast-cell activation pathway is enough to treat a heterogeneous disease.

Evommune Inc. (NYSE:EVMN) announced Monday that oral MRGPRX2 antagonist EVO756 missed the Phase IIb primary endpoint in adults with moderate-to-severe chronic spontaneous urticaria (CSU), failing to improve Urticaria Activity Score over seven days (UAS7) versus placebo at 12 weeks...